S&P Futures
6,008.25 +4.50 (+0.07%) Dow Futures
43,923.00 +13.00 (+0.03%) Nasdaq Futures
21,253.50 +28.75 (+0.14%) Russell 2000 Futures
2,398.70 +3.00 (+0.13%) Crude Oil
71.88 -0.48 (-0.66%) Gold
2,700.80 -5.00 (-0.18%)
Ocular Therapeutix, Inc. (0OT.F)
| Previous Close | 10.04 |
| Open | 0.00 |
| Bid | 0.00 x 140000 |
| Ask | 0.00 x 140000 |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 193 |
| Market Cap | 1.558B |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.43 |
GlobeNewswireOcular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Conference call and webcast to begin at 8:00 AM ETBEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and fi
- GlobeNewswire
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Pha
